RVTY

SEC Filing Summary: PerkinElmer, Inc. (Form 8-K)

Business Context and Reporting Period

This Current Report (Form 8-K) was filed on July 13, 2001, by PerkinElmer, Inc. (formerly EG&G, Inc.). The primary event reported is the Board of Directors' authorization on July 13, 2001, to sell the Company's Security and Detection Systems business. Consequently, this business unit is now classified as a discontinued operation. The filing includes audited annual financial statements for the three years ended December 31, 2000, and unaudited interim statements for the three months ended April 1, 2001. All per-share data reflects a two-for-one stock split effected on June 1, 2001.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: 2000 revenues increased 24% year-over-year, driven by organic growth (11%) and the acquisition of NEN Life Sciences. Q1 2001 revenues rose 8% compared to Q1 2000.
• Profitability: While reported Net Income decreased in 2000 compared to 1999 (due to a massive gain on the sale of the Technical Services segment in 1999), Adjusted EPS increased 22% to $1.05 in 2000. Operating income from continuing operations more than tripled in 2000 compared to 1999.
• Debt Levels: Total debt increased significantly in 2000 to fund acquisitions (NEN, AI, Lumen). Long-term debt rose from $114.9 million in 1999 to $583.3 million in 2000, primarily due to the issuance of $460 million in zero-coupon senior convertible debentures.
• Discontinued Operations: The 1999 results included a $110.3 million after-tax gain from the sale of the Technical Services segment. The 2000 results included a $2.4 million loss from discontinued operations. The Security and Detection Systems business is now also classified as discontinued.

Guidance, Outlook, and Risks

• Acquisition Activity: On July 16, 2001, the Company announced an agreement to acquire Packard BioScience for approximately $750 million in a stock merger. The transaction is expected to close by year-end 2001.
• Restructuring: The Company expects to incur $20 million to $25 million in cash outlays for restructuring plans throughout fiscal 2001. These plans aim to generate $30 million to $35 million in annual pre-tax savings.
• Capital Expenditures: Estimated capital expenditures for fiscal 2001 are projected to be between $65 million and $70 million.
• Risks and Contingencies:
  • IRS Dispute: The Company is contesting IRS deficiencies for tax years 1985-1994 totaling $74 million plus interest.
  • Environmental: The Company has accrued $8.8 million for environmental remediation but notes that a material loss exceeding recorded amounts is reasonably possible due to the preliminary stage of investigations.
  • Convertible Debt: The $460 million convertible debentures are currently convertible into 10.8 million shares at approximately $42.50 per share, which could dilute existing shareholders.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the segregation of the Security and Detection Systems business results to understand the true performance of continuing operations.
• Acquisition Integration: Assess the integration progress and financial contribution of the NEN Life Sciences acquisition, which significantly impacted 2000 results.
• Debt Service: Review the terms of the $460 million zero-coupon convertible debentures, noting the $921 million repayment obligation at maturity in 2020.
• Restructuring Execution: Monitor the realization of the projected $30-$35 million in annual savings from ongoing restructuring plans.
• Packard BioScience Deal: Track the regulatory approval and shareholder vote status for the proposed $750 million acquisition of Packard BioScience.